Takeda Completes Oncology Collaboration With Innovent, Secures Global Rights To Late-Stage Cancer Assets

Takeda has officially closed its previously announced license and collaboration agreement with Innovent Biologics after meeting all required closing conditions. First revealed on October 21, 2025, the partnership allows Takeda to expand its late-stage oncology pipeline with promising next-generation therapeutics.

Under this agreement, Takeda secures rights outside Greater China to two advanced investigational cancer therapies, IBI363 and IBI343. IBI363, currently in development for non-small cell lung cancer and colorectal cancer, has also shown potential across multiple solid tumor types. Meanwhile, IBI343 is being evaluated as a potential treatment for gastric and pancreatic cancers, addressing significant unmet medical needs in these aggressive tumor categories.

"Our collaboration with Innovent reflects the power of partnerships in oncology," said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. "By combining innovative science with global development and commercialization expertise, we can advance more options for patients with the potential to address critical treatment gaps. This agreement reflects our deep commitment to developing medicines that enhance and extend the lives of people living with cancer."

Takeda will take the lead on global co-development and U.S. co-commercialization of IBI363, while holding exclusive commercialization rights in regions beyond the United States and Greater China. For IBI343, Takeda gains exclusive worldwide rights outside Greater China for development, manufacturing, and commercialization. The company also obtains an exclusive option to license global rights to IBI3001, an early-stage investigational asset, further strengthening its future oncology portfolio.

As part of the agreement, Takeda will provide Innovent with US$1.2 billion upfront, including a US$100 million equity investment. This financial commitment will be recorded within Takeda’s fiscal year ending March 31, 2026, as noted in the company’s updated forecast published in October 2025.